PURPOSE: Global data on human papillomavirus (HPV) serological and deoxyribonucleic acid (DNA) prevalence are essential to optimize HPV prophylactic vaccination strategies. METHODS: We conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV-16, -18, -6, and -11. RESULTS: One hundred seventeen studies were included; participants' ages ranged from several hours to >90 years. HPV-16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than among men, and peaked around ages 25-40 years. HPV-18 seroprevalence was generally lower than HPV-16 with a later age peak. Data were limited for HPV-6 and -11, both of which peaked at ages similar to HPV-18. Among 9-26-year-old females, HPV-16 seroprevalence ranged from 0%-31% in North America, 21%-30% in Africa, 0%-23% in Asia/Australia, 0%-33% in Europe, and 13%-43% in Central and South America. HPV-16/-18 DNA prevalence peaked 10-15 years before corresponding HPV-16/-18 antibody prevalence. CONCLUSIONS: Females within the HPV vaccine-eligible age-group (9-26 years) had a range of dual HPV-16 DNA and serology negativity from 81%-87%, whereas 90%-98% were HPV-16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination.
PURPOSE: Global data on human papillomavirus (HPV) serological and deoxyribonucleic acid (DNA) prevalence are essential to optimize HPV prophylactic vaccination strategies. METHODS: We conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV-16, -18, -6, and -11. RESULTS: One hundred seventeen studies were included; participants' ages ranged from several hours to >90 years. HPV-16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than among men, and peaked around ages 25-40 years. HPV-18 seroprevalence was generally lower than HPV-16 with a later age peak. Data were limited for HPV-6 and -11, both of which peaked at ages similar to HPV-18. Among 9-26-year-old females, HPV-16 seroprevalence ranged from 0%-31% in North America, 21%-30% in Africa, 0%-23% in Asia/Australia, 0%-33% in Europe, and 13%-43% in Central and South America. HPV-16/-18 DNA prevalence peaked 10-15 years before corresponding HPV-16/-18 antibody prevalence. CONCLUSIONS: Females within the HPV vaccine-eligible age-group (9-26 years) had a range of dual HPV-16 DNA and serology negativity from 81%-87%, whereas 90%-98% were HPV-16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination.
Authors: I Jochmus-Kudielka; A Schneider; R Braun; R Kimmig; U Koldovsky; K E Schneweis; K Seedorf; L Gissmann Journal: J Natl Cancer Inst Date: 1989-11-15 Impact factor: 13.506
Authors: Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; Maria C Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-02 Impact factor: 4.254
Authors: Tammy S Shields; Louise A Brinton; Robert D Burk; Sophia S Wang; Stephanie J Weinstein; Regina G Ziegler; Yevgeniy Y Studentsov; Mary McAdams; Mark Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-10 Impact factor: 4.254
Authors: Gloria Y F Ho; Yevgeniy Y Studentsov; Robert Bierman; Robert D Burk Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-01 Impact factor: 4.254
Authors: J Dillner; F Wiklund; P Lenner; C Eklund; V Frederiksson-Shanazarian; J T Schiller; M Hibma; G Hallmans; U Stendahl Journal: Int J Cancer Date: 1995-01-27 Impact factor: 7.396
Authors: P Heino; C Eklund; V Fredriksson-Shanazarian; S Goldman; J T Schiller; J Dillner Journal: J Natl Cancer Inst Date: 1995-03-15 Impact factor: 13.506
Authors: J J Carter; G C Wipf; M E Hagensee; B McKnight; L A Habel; S K Lee; J Kuypers; N Kiviat; J R Daling; L A Koutsky Journal: J Infect Dis Date: 1995-07 Impact factor: 5.226
Authors: Reinhard Höpfl; Anton Petter; Petra Thaler; Mario Sarcletti; Andreas Widschwendter; Robert Zangerle Journal: BMC Infect Dis Date: 2003-04-30 Impact factor: 3.090
Authors: S S Wang; M Schiffman; T S Shields; R Herrero; A Hildesheim; M C Bratti; M E Sherman; A C Rodriguez; P E Castle; J Morales; M Alfaro; T Wright; S Chen; B Clayman; R D Burk; R P Viscidi Journal: Br J Cancer Date: 2003-10-06 Impact factor: 7.640
Authors: S S Wang; M Schiffman; R Herrero; J Carreon; A Hildesheim; A C Rodriguez; M C Bratti; M E Sherman; J Morales; D Guillen; M Alfaro; B Clayman; R D Burk; R P Viscidi Journal: Br J Cancer Date: 2004-10-04 Impact factor: 7.640
Authors: Shams Rahman; Christine M Pierce Campbell; Tim Waterboer; Dana E Rollison; Donna J Ingles; B Nelson Torres; Angelika Michel; Staci L Sudenga; Michael Pawlita; Luisa L Villa; Eduardo Lazcano Ponce; Amy R Borenstein; Wei Wang; Anna R Giuliano Journal: J Gen Virol Date: 2016-10-06 Impact factor: 3.891
Authors: Beibei Lu; Raphael P Viscidi; Yougui Wu; Alan G Nyitray; Luisa L Villa; Eduardo Lazcano-Ponce; Roberto J Carvalho da Silva; Maria Luiza Baggio; Manuel Quiterio; Jorge Salmerón; Danelle C Smith; Martha Abrahamsen; Mary Papenfuss; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-07-03 Impact factor: 4.254
Authors: Asha A Elmi; Devendra Bansal; Anushree Acharya; Sini Skariah; Soha R Dargham; Laith J Abu-Raddad; Nady Mohamed-Nady; Paul Amuna; Asma A J Al-Thani; Ali A Sultan Journal: PLoS One Date: 2017-01-03 Impact factor: 3.240